Kelly Dooley, MD

CRS:

JHU

Role:

Investigators

Position:

Co-investigator

Email:

kdooley1@jhmi.edu

Dr. Dooley is an Associate Professor of Medicine, Pharmacology, and Molecular Sciences at Johns Hopkins University School of Medicine, with appointments in the Divisions of Clinical Pharmacology and Infectious Diseases. She is also a faculty member at the Center for Clinical Global Health Education.

Dr. Dooley has an HIV outpatient practice and attends on the inpatient HIV service. Her research focuses on tuberculosis therapeutics with an emphasis on Phase I or II clinical trials of new or existing TB drugs and treatment of HIV/TB co-infection. She is Principal Investigator or Protocol Chair for several clinical trials involving TB drugs for drug-sensitive TB or drug-resistant TB and involved in the scientific committees of the Tuberculosis Trials Consortium, AIDS Clinical Trials Group, and IMPAACT networks. She has a special interest in optimizing TB drugs for special populations, including children and pregnant women.

Dr. Dooley received her MD from Duke University, and completed residency training in internal medicine and an infectious diseases fellowship at Johns Hopkins School of Medicine. She is board certified in internal medicine and infectious diseases.

  • Member, ACTG Tuberculosis TSG and IMPAACT TB Scientific Committee
  • Protocol chair, IMPAACT P2005
  • Protocol co-chair, ACTG 5343, ACTG 5312
  • Protocol vice chair IMPAACT 2001
  • Protocol Team Member ACTG 5338, ACTG 5300, IMPAACT 1108
  • Pharmacologist, Tuberculosis Transformative Science Group (Dec 2015-17)
  • Multidrug-resistant TB Working Group of TB TSG (Oct 2014)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More